A smartphone platform that helps doctors monitor Parkinson’s symptoms has raised US$5.6m to expand its commercial capacity and advance dementia-monitoring technology.
The funding brings total investment to US$11.2m for the clinically validated system, which uses smartphones to track changes in movement, speech and cognition.
Kneu Health’s platform includes a tremor measurement tool cleared by the FDA for adults with mild to moderate Parkinson’s disease.
It uses smartphone sensors to assess symptom severity and measure changes in voice, balance, walking pattern, reaction time and thinking ability through structured digital tests.
Caroline Cake, Kneu Health co-founder and chief executive officer, said: “This funding allows us to bring that model to the US at the right moment, when health systems are ready to move beyond band-aid solutions and embrace continuous neurological care as core infrastructure, accessible to anyone with a smartphone.”
Parkinson’s disease develops when nerve cells that produce dopamine — a brain chemical that controls movement — begin to die.
This leads to motor symptoms such as tremor and balance problems, along with non-motor effects including changes in memory and speech.
Patients often face long waits between specialist appointments, meaning care can lag behind symptom progression.
The platform aims to bridge that gap by integrating continuous monitoring into everyday life and clinical routines.
The system uses artificial intelligence models to turn voice, movement and memory data into predictive biomarkers — measurable signs of disease — helping detect neurological decline earlier.
A study in Parkinson’s patients showed that the platform’s assessments aligned with standard clinical questionnaires and were sensitive to daily symptom changes.
The data also forecast clinical outcomes such as fall risk, disease progression and cognitive decline up to 18 months in advance.
Cake said: “We’ve spent the last two years proving that remote monitoring can transform neurological care.
“Clinicians are getting clearer insight without added workload, patients no longer face months of uncertainty between visits, and gain confidence that changes will be recognised rather than missed.”
The company said that in more than half of users, data from the platform supported medication changes, while 67 per cent gained faster access to treatment.
Patients also reported up to a 30 per cent improvement in confidence and self-management.
Pilot studies within the NHS showed the platform helped reduce emergency admissions and shift Parkinson’s care from reactive to planned management, according to Kneu.
